Engaging high and low burden countries in the “TB end game”

Marais, Ben J.; Outhred, Alexander C.; Zumla, Alimuddin

doi:10.1016/j.ijid.2016.03.015

Cited by 6 publications

(1 citation statement)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…26 The key to optimal infection control is rapid genotypic resistance testing to identify likely drug resistance at the earliest time point possible and to ensure that an effective treatment regimen is commenced from the very beginning. [27][28][29] Isolation and infection control isolation confer hardship and anxieties for patients, healthcare workers and family members and may further perpetuate stigmatization of MDR-TB. In addition one must weigh the safety of the public and the patient's community contacts versus the morale and well being of the patient and the available resources required to isolate the patient beyond the recommended time frame.…”

Section: Discussionmentioning

confidence: 99%

De-isolation of patients with pulmonary tuberculosis after start of treatment — clear, unequivocal guidelines are missing

Petersen¹,

Khamis

Migliori

et al. 2017

International Journal of Infectious Diseases

View full text Add to dashboard Cite

The study review guidelines on isolation of patients with tuberculosis, TB, from the World Health Organization, WHO, Centers for Disease Control and Prevention, CDC, and the European Center for Disease Control, ECDC. The review found that unequivocal guidelines for removing patients out of negative-pressure isolation and de-isolation patients from either single rooms or isolation at home is needed. Studies show that the time of effective treatment is the key parameter to follow to determine if patients are contagious to others or not. This means that standard treatment of multi-drug resistant, MDR, TB will not result in the patient being non-infectious. Thus it is important right from the time of diagnosis to know if the patient is infected with MDR TB or not. Thus the early use of molecular techniques to reveal drug susceptibility is important. Clear guidelines stating if patient with microscopy negative sputum no matter infected with fully susceptible or MDR TB, no matter HIV positive or not is needed.

show abstract

Section: Discussionmentioning

confidence: 99%

De-isolation of patients with pulmonary tuberculosis after start of treatment — clear, unequivocal guidelines are missing

Petersen¹,

Khamis

Migliori

et al. 2017

International Journal of Infectious Diseases

View full text Add to dashboard Cite

show abstract

Isoniazid Hybrids As Potential Antitubercular Agents

Mishra,

Kumar,

Singh

2024

ChemistrySelect

View full text Add to dashboard Cite

The rapid emergence of various forms of drug‐resistant tuberculosis (TB) has massively impacted people's health globally. According to the WHO, TB care and facilities have been downgraded by 21% since the COVID‐19 pandemic, which has further slowed down the progress toward the “End TB Strategy.” Multiple studies have shown drug‐resistant tuberculosis to be resilient to front‐line antituberculosis drugs, including isoniazid (INH), thus constantly prompting researchers worldwide to probe new potent chemical entities to replace/supplement the current artillery of anti‐TB therapeutics. The molecular hybridization (MH) technique has recently been adopted by many synthetic and medicinal chemists to combine different pharmacophoric units into a single molecular architecture which in most cases has been reported to exhibit a better pharmacological profile as compared to its precursors. The present review provides a concise account of the MH hybridization strategies directed at the structural manipulations of isoniazid to develop new anti‐TB agents and their structure‐activity relationships. Furthermore, their toxicity profiles and docking studies with relevant receptors are also briefly discussed.

show abstract